Frankfurt - Delayed Quote EUR

GenSight Biologics S.A. (G49N.F)

0.2325

+0.0080

+(3.56%)

At close: April 28 at 8:18:31 AM GMT+2

GenSight Biologics Annual General Meeting on May 13, 2025

PARIS, April 23, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 13, 2025, at 2:00 pm CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.

Business Wire 5 days ago

GSGTF
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

PARIS, April 08, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced the filing on April 7, 2025 of its 2024 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF).

Business Wire 20 days ago

GSGTF
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

PARIS, April 07, 2025--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2025, and provided a business update.

Business Wire 21 days ago

GSGTF
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

PARIS, March 19, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2024 are in line with the estimated figures published on February 27, 2025.

Business Wire last month

GSGTF
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

PARIS, March 17, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Tucson, Arizona, USA (March 15-20,

Business Wire last month

GSGTF
GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors

PARIS, March 07, 2025--Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia

Business Wire last month

GSGTF
GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

PARIS, February 27, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year 2024 consolidated financial results1, as reviewed by the Audit Committee and approved by the Board of Directors on February 26, 2025. The Board of Directors will approve the final a

Business Wire last month

GSGTF
GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years

The five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition that can lead to blindness.

Clinical Trials Arena 2 months ago

SIGHT.PA
-8.09%
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study

PARIS, February 12, 2025--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211039390/en/

Business Wire 2 months ago

GSGTF
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

PARIS, January 23, 2025--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of December 31, 2024, and provided a business update.

Business Wire 3 months ago

GSGTF
GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

PARIS, January 15, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of outcomes data from five years’ follow-up of patients treated unilaterally with LUMEVOQ®, the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due t

Business Wire 3 months ago

GSGTF
GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

PARIS, December 18, 2024--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided an update on its regulatory discussions with the French medicines safety agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé or the ANSM)

Business Wire 4 months ago

GSGTF
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

PARIS, November 13, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ® gene therapy to the French medicines safety agency Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) to prepare for

Business Wire 5 months ago

GSGTF
GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors

PARIS, November 01, 2024--Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia

Business Wire 5 months ago

GSGTF
GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

PARIS, October 28, 2024--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027820028/en/

Business Wire 5 months ago

GSGTF
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

PARIS, October 24, 2024--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2024, and provided a business update.

Business Wire 6 months ago

GSGTF
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

PARIS, October 17, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 2024 annual meeting of the American Academy of Ophthalmology (AAO) in Chicago, Illinois (October 18-21, 2024).

Business Wire 6 months ago

GSGTF
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

PARIS, September 23, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2024, and provided business updates since June.

Business Wire 7 months ago

GSGTF
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

PARIS, July 23, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2024, and provided a business update.

Business Wire 9 months ago

GSGTF
GenSight Biologics Launches Newsletter for Retail Investors

PARIS, July 11, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today published the first issue of a company newsletter aimed at retail investors in France. The quarterly newsletter will be published in French and will be available via the company’s website and by subscription.

Business Wire 9 months ago

GSGTF

Performance Overview

Return	G49N.F	CAC 40 (^FCHI)
YTD	-0.85%	+2.62%
1-Year	-38.33%	-6.36%
3-Year	-88.21%	+16.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GenSight Biologics S.A. (G49N.F)

GenSight Biologics Annual General Meeting on May 13, 2025

GenSight Biologics Announces the Filing of its 2024 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update

GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors

GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results

GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years

GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study

GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update

GenSight Biologics Announces Publication of 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ® Gene Therapy

GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors

GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

GenSight Biologics Launches Newsletter for Retail Investors

Performance Overview